Company logo

VAXX - Vaxxinity, Inc.

NASDAQ -> Healthcare -> Biotechnology
Dallas, United States
Type: Equity

VAXX price evolution
VAXX
(in millions $) 31 Jan 2024 30 Oct 2023 30 Jul 2023 1 May 2023
Current assets
Cash
Short term investments
Net receivables $0.41 $0.4 $0.41 $0.52
Inventory
Total current assets $33.23 $46.4 $59.7 $73.43
Long term investments
Property, plant & equipment $11.08 $11.1 $11.66 $12.1
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $44.31 $57.5 $71.37 $85.53
Current liabilities
Accounts payable $1.78 $3 $1.89 $3.03
Deferred revenue
Short long term debt
Total current liabilities $17.61 $21.6 $23.78 $26.47
Long term debt $13.26 $12 $12.34 $12.69
Total noncurrent liabilities
Total debt
Total liabilities $30.9 $33.8 $36.35 $39.4
Shareholders' equity
Retained earnings -$361.64 -$350.2 -$337.1 -$323.12
Other shareholder equity $0.01 -$0.02 -$0.05
Total shareholder equity
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Current assets
Cash
Short term investments
Net receivables $0.41 $0.41 $0.39 $0.39
Inventory
Total current assets $33.23 $93.89 $154.13 $35.67
Long term investments
Property, plant & equipment $11.08 $12.51 $12.17 $12.16
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $44.31 $106.4 $166.67 $50.14
Current liabilities
Accounts payable $1.78 $5.29 $3.19 $1.02
Deferred revenue
Short long term debt
Total current liabilities $17.61 $30.94 $27.49 $37.22
Long term debt $13.26 $13.04 $10.32 $10.7
Total noncurrent liabilities
Total debt
Total liabilities $30.9 $44.22 $38.05 $75.04
Shareholders' equity
Retained earnings -$361.64 -$304.7 -$229.48 -$92.31
Other shareholder equity $0.01 -$0.2
Total shareholder equity
(in millions $) 31 Jan 2024 30 Oct 2023 30 Jul 2023 1 May 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $11.65 $13.45 $14.43 $18.81
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense $0.26 $0.3 $0.45 $0.39
Net income
Net income -$11.39 -$13.15 -$13.98 -$18.42
Income (for common shares)
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Revenue
Total revenue $0.07 $0.56
Cost of revenue
Gross Profit -$1.87 $0.51
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $58.28 $75.98 $123.2 $32.79
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense $1.35 $0.76 -$0.85 -$1.26
Net income
Net income -$56.93 -$75.22 -$137.18 -$39.96
Income (for common shares)
(in millions $) 31 Jan 2024 30 Oct 2023 30 Jul 2023 1 May 2023
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing $28.84 $29.25 $35.35 $8.74
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing -$1.14 -$0.83 -$0.45 -$0.57
Effect of exchange rate
Change in cash and equivalents -$29.53 -$16.97 $2.69 -$11.88
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing $28.84 -$54.39 -$1.32 -$1.48
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing -$1.14 -$0.17 $196.17 $66.11
Effect of exchange rate
Change in cash and equivalents -$29.53 -$110.49 $113.86 $30.72
Fundamentals
Market cap $25.35K
Enterprise value N/A
Shares outstanding 126.75M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income -$56.94M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -0.00
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$0.45
ROA -88.04%
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 1.89
Quick ratio N/A